The deregulation of PRC2 in CML LSCs led to epigenetic modification at H3K27, while inhibition of EZH2 or treatment with TKIs significantly increased methylation at H3K27. This evidence concerns the gene EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive.